Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Transplantation. 2010 Jul 27;90(2):124-6. doi: 10.1097/TP.0b013e3181ea4240.
There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.
人们对间充质干细胞(MSC)在实体器官移植中的应用越来越感兴趣。临床前移植模型表明 MSC 可延长移植物存活时间,并且已经计划或正在开展多项临床研究。在最近举行的 MISOT 联盟(MSC 在实体器官移植中的作用)会议上,评估了这些研究的进展,并讨论了 MSC 潜在作用的机制。需要进一步讨论,以确定 MSC 治疗实体器官移植的安全性和最终疗效终点。